Answers are grounded in this paper and cite their sources.
Nontuberculous mycobacteria (NTM), particularly Mycobacterium avium and Mycobacterium abscessus , are increasingly recognized causes of chronic pulmonary disease, yet current therapies remain prolonged treatment, are frequently associated with adverse effects, and often achieve suboptimal clinical outcomes. To identify therapeutic regimens active against both slow- and rapidly growing NTM species, we systematically evaluated 11 tuberculosis (TB) standard-of-care drugs using a tiered preclinical screening framework comprising minimum inhibitory concentration (MIC) testing, intracellular macrophage infection assays, and species-matched murine lung infection models. Initial susceptibility screening demonstrated substantial differences in drug activity between M. avium and M. abscessus , with cell wall-directed agents generally exhibiting limited cross-species activity. Bedaquiline (BDQ), an FDA-approved antimycobacterial agent, demonstrated the greatest activity among the compounds evaluated in our screening panel and was therefore selected as the foundation for subsequent combination studies. Azithromycin (AZI), clarithromycin (CLA), and ofloxacin (OFL) also emerged as promising agents for further evaluation. Following extended incubation, CLA and AZI MICs increased 2- to 4-fold in M. abscessus , consistent with inducible erm (41)-mediated macrolide resistance, whereas BDQ and OFL retained unchanged activity, supporting BDQ as a candidate therapeutic anchor. Intracellular macrophage studies confirmed BDQ as the most consistently active single agent and demonstrated enhanced bacterial clearance with BDQ + AZI; BDQ + OFL was advanced based on complementary mechanisms and favorable cross-species activity. Subsequent murine lung infection studies confirmed BDQ as the principal driver of antibacterial efficacy against both species. The BDQ + AZI and BDQ + OFL combinations emerged as two-drug therapeutic backbones with activity in both species-matched models, while optimizing the dose and schedule of the three-drug BDQ + AZI+OFL regimen produced cross-species efficacy and the greatest bacterial clearance observed in the M. abscessus model. Treatment performance was examined using complementary measures with distinct purposes: Δlog10 CFU quantified absolute bacterial clearance, Hedges’ g described standardized effect magnitude, quartile classification provided relative within-model ranking, and MACI provided secondary normalization for species-specific in vitro susceptibility. Collectively, these studies establish a systematic translational framework that down-selected 11 TB standard-of-care drugs to 3 prioritized therapeutic agents (BDQ, AZI, and OFL) and ultimately to three BDQ-anchored regimens with activity across both species-matched models. Further, these findings identify BDQ as a candidate therapeutic anchor whose activity is maintained despite inducible erm (41)-mediated macrolide resistance and support the development of modular BDQ-anchored therapeutic platforms that can be optimized for species-specific susceptibility while maintaining a common therapeutic architecture across clinically important NTM species.
No takes yet. Share an insight, caveat, or question.
Whittel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: